Stock Scorecard



Stock Summary for Ginkgo Bioworks Holdings Inc - Class A (DNA) - $9.37 as of 6/1/2026 1:38:07 PM EST

Total Score

12 out of 30

Safety Score

30 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for DNA

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for DNA

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for DNA

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for DNA

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for DNA (30 out of 100)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 1
Analyst Buy Ratings (Max of 5) 2
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for DNA

Ginkgo Bioworks Holdings (NYSE:DNA) - Stock Analysis 5/27/2026 8:39:00 PM
Ginkgo Bioworks (NYSE: DNA) insider logs RSU vesting and small tax-related share sale 5/26/2026 8:39:00 PM
Steve Coen (DNA) files Form 144 to sell 307 Class A shares 5/22/2026 7:40:00 PM
Viking Global (DNA) reports 3,577,128 shares, removes retired reporting person 5/15/2026 9:40:00 PM
Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts 5/14/2026 2:39:00 AM
Austin Che files Form 144 to sell Class A shares (NASDAQ: DNA) 5/13/2026 3:09:00 PM
Ginkgo Bioworks Holdings (DNA) TTM Net Loss Of US$312.8 Million Reinforces Bearish Narratives 5/9/2026 1:09:00 PM
Ginkgo Bioworks (NYSE: DNA) posts Q1 2026 loss and exits Biosecurity unit 5/8/2026 1:39:00 AM
DNA SEC Filings - Ginkgo Bioworks Holdings Inc 10-K, 10-Q, 8-K Forms 5/4/2026 11:39:00 AM
Will Ginkgo Bioworks Holdings (NYSE:DNA) Spend Its Cash Wisely? 4/30/2026 9:10:00 AM

Financial Details for DNA

Company Overview

Ticker DNA
Company Name Ginkgo Bioworks Holdings Inc - Class A
Country USA
Description Ginkgo Bioworks Holdings (DNA) is a pioneering entity in the synthetic biology landscape, utilizing advanced genetic engineering to craft customized bioengineered organisms across various sectors, including pharmaceuticals, agriculture, and industrial biotech. The company's state-of-the-art platform bolsters cellular design for manufacturing, driving efficiency in product development and production processes. With a strategic emphasis on addressing critical global challenges such as climate change and food security, Ginkgo is uniquely positioned to make substantial contributions across multiple industries while promoting sustainable biotechnology solutions. As the demand for bio-based alternatives intensifies, Ginkgo’s innovative approach and commitment to sustainability offer a promising trajectory for significant growth and impact.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 3/31/2026
Next Earnings Date N/A

Stock Price History

Last Day Price 9.37
Price 4 Years Ago 67.60
Last Day Price Updated 6/1/2026 1:38:07 PM EST
Last Day Volume 1,183,083
Average Daily Volume 1,224,007
52-Week High 17.58
52-Week Low 5.37
Last Price to 52 Week Low 74.49%

Valuation Measures

Trailing PE N/A
Industry PE 32.57
Sector PE 47.20
5-Year Average PE -2.72
Free Cash Flow Ratio 3.47
Industry Free Cash Flow Ratio 19.46
Sector Free Cash Flow Ratio 35.13
Current Ratio Most Recent Quarter 5.15
Total Cash Per Share 2.70
Book Value Per Share Most Recent Quarter 7.19
Price to Book Ratio 1.38
Industry Price to Book Ratio 12.11
Sector Price to Book Ratio 20.65
Price to Sales Ratio Twelve Trailing Months 3.92
Industry Price to Sales Ratio Twelve Trailing Months 9.31
Sector Price to Sales Ratio Twelve Trailing Months 4.85
Analyst Buy Ratings 1
Analyst Strong Buy Ratings 0

Share Statistics

Total Shares Outstanding 53,361,000
Market Capitalization 499,992,570
Institutional Ownership 68.65%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 42.83%
Reported EPS 12 Trailing Months -5.38
Reported EPS Past Year -1.39
Reported EPS Prior Year -5.65
Net Income Twelve Trailing Months -304,393,000
Net Income Past Year -312,763,000
Net Income Prior Year -547,029,000
Quarterly Revenue Growth YOY -49.10%
5-Year Revenue Growth 17.29%
Operating Margin Twelve Trailing Months -366.50%

Balance Sheet

Total Cash Most Recent Quarter 143,864,000
Total Cash Past Year 167,202,000
Total Cash Prior Year 561,572,000
Net Cash Position Most Recent Quarter 143,864,000
Net Cash Position Past Year 167,202,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 508,590,000
Total Stockholder Equity Prior Year 716,058,000
Total Stockholder Equity Most Recent Quarter 443,153,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -190,927,000
Free Cash Flow Per Share Twelve Trailing Months -3.58
Free Cash Flow Past Year -178,724,000
Free Cash Flow Prior Year -382,126,000

Options

Put/Call Ratio 1.33
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.12
MACD Signal 0.11
20-Day Bollinger Lower Band 0.00
20-Day Bollinger Middle Band 0.00
20-Day Bollinger Upper Band 0.00
Beta 1.78
RSI 0.00
50-Day SMA 9.83
150-Day SMA 24.91
200-Day SMA 38.76

System

Modified 6/1/2026 9:50:54 PM EST